Mangoceuticals, Inc.
MGRX
$1.73
-$0.07-3.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 3.90% | -21.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.90% | -21.14% | |||
| Cost of Revenue | 88.05% | -50.49% | |||
| Gross Profit | -22.47% | -3.14% | |||
| SG&A Expenses | 100.71% | 9.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 42.38% | 52.08% | |||
| Operating Income | -44.09% | -58.57% | |||
| Income Before Tax | -148.36% | 2.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -148.36% | 2.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -50.00% | -60.00% | |||
| Net Income | -148.38% | 2.54% | |||
| EBIT | -44.09% | -58.57% | |||
| EBITDA | -81.69% | -10.57% | |||
| EPS Basic | 2.11% | -8.42% | |||
| Normalized Basic EPS | -41.73% | 25.11% | |||
| EPS Diluted | 2.11% | -8.42% | |||
| Normalized Diluted EPS | -41.73% | 25.11% | |||
| Average Basic Shares Outstanding | 75.26% | 30.14% | |||
| Average Diluted Shares Outstanding | 75.26% | 30.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||